M3 Valuation

Is 4YC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 4YC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 4YC (€8.8) is trading above our estimate of fair value (€7.1)

Significantly Below Fair Value: 4YC is trading above our estimate of fair value.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 4YC?

Other financial metrics that can be useful for relative valuation.

4YC key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue3.6x
Enterprise Value/EBITDA12.1x
PEG Ratio2.2x

Price to Earnings Ratio vs Peers

How does 4YC's PE Ratio compare to its peers?

The above table shows the PE ratio for 4YC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average23.8x
COP CompuGroup Medical SE KGaA
26.2x26.1%€1.3b
NXU Nexus
38.6x15.5%€961.6m
AFX Carl Zeiss Meditec
22.1x12.1%€5.8b
M3V MeVis Medical Solutions
8.4xn/a€48.4m
22.5x10.3%€1.0t

Price-To-Earnings vs Peers: 4YC is good value based on its Price-To-Earnings Ratio (22.5x) compared to the peer average (23.8x).


Price to Earnings Ratio vs Industry

How does 4YC's PE Ratio compare vs other companies in the European Healthcare Services Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a28.1%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a28.1%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: 4YC is expensive based on its Price-To-Earnings Ratio (22.5x) compared to the European Healthcare Services industry average (17.8x).


Price to Earnings Ratio vs Fair Ratio

What is 4YC's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

4YC PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio22.5x
Fair PE Ratio30.4x

Price-To-Earnings vs Fair Ratio: 4YC is good value based on its Price-To-Earnings Ratio (22.5x) compared to the estimated Fair Price-To-Earnings Ratio (30.4x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 4YC forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€8.80
€13.02
+47.9%
25.4%€20.57€8.29n/a13
Jun ’25€8.60
€13.40
+55.8%
26.0%€20.65€8.32n/a12
May ’25€9.50
€14.71
+54.8%
22.1%€20.79€9.98n/a12
Apr ’25€13.00
€15.85
+21.9%
20.2%€22.10€12.28n/a12
Mar ’25€13.10
€16.69
+27.4%
23.3%€24.50€12.25n/a11
Feb ’25€13.80
€17.85
+29.4%
19.4%€25.15€13.83n/a11
Jan ’25€14.60
€18.42
+26.2%
24.7%€30.09€13.88n/a11
Dec ’24€14.50
€18.42
+27.0%
24.7%€30.09€13.88n/a11
Nov ’24€14.50
€21.33
+47.1%
22.5%€30.55€14.09n/a13
Oct ’24€16.90
€23.98
+41.9%
22.3%€39.27€17.73n/a13
Sep ’24€18.20
€24.59
+35.1%
21.1%€39.37€17.78n/a14
Aug ’24€20.20
€25.27
+25.1%
20.5%€39.86€19.61n/a14
Jul ’24€19.40
€25.26
+30.2%
20.1%€38.25€19.13n/a14
Jun ’24€20.60
€26.69
+29.6%
19.6%€40.18€20.09€8.6014
May ’24€21.00
€28.04
+33.5%
19.3%€39.77€19.89€9.5014
Apr ’24€22.60
€31.18
+38.0%
22.4%€51.22€21.75€13.0014
Mar ’24€22.00
€32.85
+49.3%
23.1%€51.02€25.16€13.1013
Feb ’24€24.60
€34.64
+40.8%
20.8%€50.70€26.05€13.8013
Jan ’24€25.00
€34.62
+38.5%
19.7%€49.94€25.66€14.6013
Dec ’23€29.20
€35.41
+21.3%
20.2%€50.05€25.72€14.5013
Nov ’23€30.20
€34.58
+14.5%
19.4%€47.59€25.16€14.5013
Oct ’23€28.20
€35.63
+26.3%
20.3%€49.45€26.14€16.9013
Sep ’23€31.20
€37.73
+20.9%
24.3%€60.88€27.14€18.2013
Aug ’23€34.20
€36.03
+5.4%
25.9%€59.57€24.76€20.2013
Jul ’23€26.40
€35.87
+35.9%
24.5%€57.88€24.35€19.4013
Jun ’23€27.00
€36.95
+36.9%
25.5%€59.35€24.97€20.6014

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.